Tarsus Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Tarsus Pharmaceuticals Inc (TARS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.9% of the shares are freely tradable; institutional investors hold 109.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.62 | 3,666,768 | +1.9 | 06/30/2026 |
| BlackRock Inc | 8.35 | 3,552,612 | -6.3 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 7.86 | 3,346,025 | +0.3 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 6.52 | 2,775,649 | +8.3 | 06/30/2026 |
| HHG PLC | 5.27 | 2,240,963 | +16.1 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 4.57 | 1,944,272 | -4.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.14 | 1,760,541 | +0.0 | 03/31/2026 |
| Jennison Associates LLC | 3.91 | 1,663,655 | -2.8 | 06/30/2026 |
| Millennium Management LLC | 3.35 | 1,427,124 | +152.8 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.06 | 1,301,803 | +0.5 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair | 827,991 | 65,411,289 $ | Sep 4, 2026 | indirect |
| Neervannan Seshadri | Chief Operating Officer | 78,532 | 6,204,028 $ | Sep 4, 2026 | direct |
| Lin Elizabeth Yeu | Chief Medical Officer | 4,137 | 326,823 $ | Sep 4, 2026 | both |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 1,590 | 90.00 | 143,100 |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5,386 | 90.00 | 484,740 |
| Sep 4, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5,387 | 85.00 | 457,895 |
| Sep 4, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 2,900 | 91.27 | 264,683 |
| Sep 4, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 7,100 | 90.27 | 640,917 |
| Sep 4, 2026 | Neervannan Seshadri | Chief Operating Officer | Sell | 4,564 | 85.00 | 387,940 |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 1,590 | 80.00 | 127,200 |
| Sep 2, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 5,387 | 80.00 | 430,960 |
| Sep 2, 2026 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 10,000 | 80.06 | 800,600 |
| Sep 1, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 4,601 | 73.86 | 339,830 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.